Sonnet BioTherapeutics Competitors and Similar CompaniesClear all
Sonnet BioTherapeutics's competitors and similar companies include ImmunityBio and MABION.
 Sonnet BioTherapeutics Sonnet BioTherapeutics (formerly known as Chanticleer Holdings) is an oncology-focused biotechnology company. |  ImmunityBio ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. |  MABION Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases. | |
Founding Date | Founding Date 2011 | Founding Date 2014 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Princeton, US HQ | Locations Culver City, US HQ San Diego, US Woburn, US | Locations Konstantynów Łódzki, PL HQ |
Employees | Employees 12 | Employees 16116% increase | Employees 95 |
Valuation ($) | Valuation ($) 2.9 m | Valuation ($) 4.3 b | Valuation ($) 21.7 m |
Financial | |||
Revenue (est.) | Revenue (est.) $1m (FY, 2025) | Revenue (est.) $113.3m (FY, 2025) | Revenue (est.) zł15.8m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $753k (FY, 2025) | Cost of goods zł24.1m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $112.5m (FY, 2025) | Gross profit (zł7.2m) (FY, 2025) |
Net income | Net income ($16m) (FY, 2025) | Net income ($351.5m) (FY, 2025) | Net income (zł62.6m) (FY, 2025) |
For sources of this data, please see the company profile
View Company Profiles
ImmunityBio
HQ
Culver City, US
Employees
161↑ 16% increase
ImmunityBio (formerly known as NantKwest) is a clinical-stage immunotherapy company focused on harnessing the power of the immune system using natural killer cells to treat cancer, infectious diseases, and inflammatory diseases.
View companyMABION
HQ
Konstantynów Łódzki, PL
Employees
95
Mabion is a biotechnology company engaged in research and development of biotechnology and biosimilar drugs to treat cancer, autoimmune, and metabolic diseases.
View company